Long-term viral negativity after Interferon for chronic hepatitis C virus infection in hemodialysis

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 9, 2011, Pages 2226-2234

  Gordon, Craig E ^a   Uhlig, Katrin ^b   Schmid, Christopher H ^b   Levey, Andrew S ^a   Wong, John B ^b  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ARTICLE; CHRONIC KIDNEY DISEASE; FOLLOW UP; GRAFT RECIPIENT; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; KIDNEY TRANSPLANTATION; LONG TERM CARE; LONG TERM VIRAL NEGATIVITY; META ANALYSIS; OUTCOME ASSESSMENT; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS EXAMINATION;

ADULT; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; KIDNEY TRANSPLANTATION; MALE; RENAL DIALYSIS; RNA, VIRAL;

EID: 80052557704     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.00410111     Document Type: Article

References (50)

1. World Health Organization: Weekly Epidemiological Record. 49: December 10, 1999
2. Fissell RB, Bragg-Gresham JL, Woods JD, Jadoul M, Gillespie B, Hedderwick SA, Rayner HC, Greenwood RN, Akiba T, Young EW: Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: The DOPPS. Kidney Int 65: 2335-2342, 2004
3. Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, Miller LG, Daar ES, Gjertson DW, Kopple JD, Greenland S: Hepatitis C virus and death risk in hemodialysis patients. J Am Soc Nephrol 18: 1584-1593, 2007
4. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G: Metaanalysis: Effect of hepatitis C virus infection on mortality in dialysis. Aliment Pharmacol Ther 20: 1271-1277, 2004
5. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G: Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant 5: 1452-1461, 2005
6. Watanabe H, Saito T, Shinzawa H, Okumoto K, Hattori E, Adachi T, Takeda T, Sugahara K, Ito JI, Saito K, Togashi H, Suzuki R, Hayashi M, Miyamura T, Matsuura Y, Kawata S: Spontaneous elimination of serum hepatitis C virus (HCV) RNA in chronic HCV carriers: A population-based cohort study. J Med Virol 71: 56-61, 2003
7. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 358: 958-965, 2001
8. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975-982, 2002
9. Camma C, Giunta M, Pinzello G, Morabito A, Verderio P, Pagliaro L: Chronic hepatitis C and interferon alpha: Conventional and cumulative meta-analyses of randomized controlled trials. Am J Gastroenterol 94: 581-595, 1999
10. Dalgard O: Follow-up studies of treatment for hepatitis C virus infection among injection drug users. Clin Infect Dis 40 [Suppl 5]: S336-S338, 2005
11. Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, Kilani A, Areias J, Auperin A, Benhamou JP, Degott C, Erlinger S: Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 127: 875-881, 1997
12. Formann E, Steindl-Munda P, Hofer H, Jessner W, Bergholz U, Gurguta C, Ferenci P: Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy. Aliment Pharmacol Ther 23: 507-511, 2006
13. Veldt BJ, Saracco G, Boyer N, Camma C, Bellobuono A, Hopf U, Castillo I, Weiland O, Nevens F, Hansen BE, Schalm SW: Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut 53: 1504-1508, 2004
14. Reichard O, Glaumann H, Fryden A, Norkrans G, Wejstal R, Weiland O: Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon. J Hepatol 30: 783-787, 1999
15. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, Nishiguchi S, Kuroki T, Imazeki F, Yokosuka O, Kinoyama S, Yamada G, Omata M: Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 131: 174-181, 1999
16. Bruno S, Battezzati PM, Bellati G, Manzin A, Maggioni M, Crosignani A, Borzio M, Solforosi L, Morabito A, Ideo G, Podda M: Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C. J Hepatol 34: 748-755, 2001
17. Yoshida H, Arakawa Y, Sata M, Nishiguchi S, Yano M, Fujiyama S, Yamada G, Yokosuka O, Shiratori Y, Omata M: Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 123: 483-491, 2002
18. Gordon CE, Uhlig K, Lau J, Schmid CH, Levey AS, Wong JB: Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: A systematic review of the literature and meta-analysis of treatment efficacy and harms. Am J Kidney Dis 51: 263-277, 2008
19. Rostaing L, Modesto A, Baron E, Cisterne JM, Chabannier MH, Durand D: Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Nephron 74: 512-516, 1996
20. Rostaing L, Izopet J, Baron E, Duffaut M, Puel J, Durand D: Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation 59: 1426-1431, 1995
21. Kamar N, Sandres-Saune K, Selves J, Ribes D, Cointault O, Durand D, Izopet J, Rostaing L: Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology. Am J Kidney Dis 42: 184-192, 2003
22. Gordon CE, Uhlig K, Lau J, Schmid CH, Levey AS, Wong JB: Interferon for hepatitis C virus in hemodialysis-an individual patient meta-analysis of factors associated with sustained virological response. Clin J Am Soc Nephrol 4: 1449-1458, 2009
23. Bizollon T, Ahmed SN, Radenne S, Chevallier M, Chevallier P, Parvaz P, Guichard S, Ducerf C, Baulieux J, Zoulim F, Trepo C: Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence. Gut 52: 283-287, 2003
24. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB: Metaanalysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283: 2008-2012, 2000
25. Buargub M, El Huni S, Tagdi M: Tolerance and efficacy of interferon-alpha in hemodialysis patients in Tripoli. Saudi J Kidney Dis Transpl 17: 338-343, 2006
26. Campistol JM, Esforzado N, Martinez J, Rosello L, Veciana L, Modol J, Casellas J, Pons M, de Las Cuevas X, Piera J, Oliva JA, Costa J, Barrera JM, Bruguera M: Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre-and post-renal transplantation assessment. Nephrol Dial Transplant 14: 2704-2709, 1999
27. Chan TM, Wu PC, Lau JY, Lok AS, Lai CL, Cheng IK: Interferon treatment for hepatitis C virus infection in patients on haemodialysis. Nephrol Dial Transplant 12: 1414-1419, 1997
28. Espinosa M, Rodriguez M, Martin-Malo A, Alvarez de Lara MA, Gonzalez R, Lopez-Rubio F, de la Mata M, Aljama P: Interferon therapy in hemodialysis patients with chronic hepatitis C virus infection induces a high rate of long-term sustained virological and biochemical response. Clin Nephrol 55: 220-226, 2001
29. Fernandez JL, Rendo P, del Pino N, Viola L: A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV infection. Journal Viral Hepat 4: 113-119, 1997
30. Hanrotel C, Toupance O, Lavaud S, Thiefin G, Brodard V, Ingrand D, Diebold MD, Wynckel A, Chanard J: Virological and histological responses to one year alpha-interferon-2a in hemodialyzed patients with chronic hepatitis C. Nephron 88: 120-126, 2001
31. Huraib S, Tanimu D, Romeh SA, Quadri K, Al Ghamdi G, Iqbal A, Abdulla A: Interferon-alpha in chronic hepatitis C infection in dialysis patients. Am J Kidney Dis 34: 55-60, 1999
32. Izopet J, Rostaing L, Moussion F, Alric L, Dubois M, That HT, Payen JL, Duffaut M, Durand D, Suc JM, Puel J: High rate of hepatitis C virus clearance in hemodialysis patients after interferon-alpha therapy. Journal Infec Dis 176: 1614-1617, 1997
33. Mousa DH, Abdalla AH, Al-Shoail G, Al-Sulaiman MH, Al-Hawas FA, Al-Khader AA: Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. Transplantation Proc 36: 1831-1834, 2004
34. Okuda K, Hayashi H, Yokozeki K, Kondo T, Kashima T, Irie Y: Interferon treatment for chronic hepatitis C in haemodialysis patients: Suggestions based on a small series. J Gastroenterol Hepatol 10: 616-620, 1995
35. Ozdemir FN, Akcay A, Sezer S, Boyacioglu S, Ozdemir BH, Arat Z, Haberal M: A six-year follow-up after interferon-alpha monotherapy for chronic hepatitis C infection in hemodialysis patients. Ren Fail 26: 583-588, 2004
36. Pol S, Thiers V, Carnot F, Zins B, Romeo R, Berthelot P, Brechot C: Efficacy and tolerance of alpha-2b interferon therapy on HCV infection of hemodialyzed patients. Kidney Int 47: 1412-1418, 1995
37. Raptopoulou-Gigi M, Spaia S, Garifallos A, Xenou P, Orphanou H, Zarafidou E, Petridou P, Vrettou H, Vagionas G, Galaktidou G and et al: Interferon-alpha 2b treatment of chronic hepatitis C in haemodialysis patients. Nephrol Dial Transplant 10: 1834-1837, 1995
38. Casanovas-Taltavull T, Baliellas C, Benasco C, Serrano TT, Casanova A, Perez JL, Guerrero L, Gonzalez MT, Andres E, Gil-Vernet S, Casais LA: Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation. Am J Gastroenterol 96: 1170-1177, 2001
39. Huraib S, Iqbal A, Tanimu D, Abdullah A: Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. Am J Nephrol 21: 435-440, 2001
40. Kamar N, Toupance O, Buchler M, Sandres-Saune K, Izopet J, Durand D, Rostaing L: Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol 14: 2092-2098, 2003
41. Ucmak H, Kokoglu OF, Hosoglu S, Dogan E, Sayarlioglu H, Kuzhan N, Isik IO: Long-term efficacy of pegylated interferon alpha-2a in HCV-positive hemodialysis patients. Ren Fail 30: 227-232, 2008
42. Amarapurkar DN, Patel ND, Kirpalani AL: Monotherapy with peginterferon alpha-2b {12 kDa} for chronic hepatitis C infection in patients undergoing haemodialysis. Trop Gastroenterol 28: 16-18, 2007
43. Bruchfeld A, Lindahl K, Reichard O, Carlsson T, Schvarcz R: Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat 13: 316-321, 2006
44. Dzekova P, Asani A, Selim G, Gelev S, Trajceska L, Amitov V, Selja N, Zabzun M, Mena S, Gaseva M, Sikole A: Longterm follow up of sustained viral response after treatment of hepatitis C with pegylated interferon alpha-2a in hemodialysis patients. Int J Artif Organs 32: 180-184, 2009
45. Kose S, Gurkan A, Akman F, Kelesoglu M, Uner U: Treatment of hepatitis C in hemodialysis patients using pegylated interferon alpha-2a in Turkey. J Gastroenterol 44: 353-358, 2009
46. Zoppoli G, DiMaio G, Artioli S, Robaudo C, Basso M, Torre F, Cannella G, Picciotto A: Monotherapy with pegylated interferon alpha-2a in hemodialyzed patients with chronic hepatitis C. Dialysis and Transplantation 37: 204-208, 2008
47. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339: 1485-1492, 1998
48. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J: Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352: 1426-1432, 1998
49. Zeuzem S, Teuber G, Naumann U, Berg T, Raedle J, Hartmann S, Hopf U: Randomized, double-blind, placebo-controlled trial of interferon alfa2a with and without amantadine as initial treatment for chronic hepatitis C. Hepatology 32: 835-841, 2000
50. Arrais TC, Van Dooren S, Vandamme AM, Brechot C, Rimlinger F, Silva AE, Perez RM, Ferraz ML, Thiers V: Change in hepatitis C virus genotype in hemodialysis patients after endof-treatment response to interferon monotherapy-relapse or re-infection? J Med Virol 80: 80-86, 2008